Localization of Sites of Osimertinib Action in Rat Intestine, Skin, and Lung by Immunohistochemistry

IF 1.6 4区 生物学 Q4 CELL BIOLOGY
Yuta Yamamoto, Tetsuya Saita, Hiroto Kataoka, Rintaro Sogawa, Sakiko Kimura, Shinya Kimura, Chisato Shimanoe, Masashi Shin
{"title":"Localization of Sites of Osimertinib Action in Rat Intestine, Skin, and Lung by Immunohistochemistry","authors":"Yuta Yamamoto, Tetsuya Saita, Hiroto Kataoka, Rintaro Sogawa, Sakiko Kimura, Shinya Kimura, Chisato Shimanoe, Masashi Shin","doi":"10.1267/ahc.23-00055","DOIUrl":null,"url":null,"abstract":"</p><p>Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations and has shown efficacy in patients with non-small-cell lung cancer. In this study, we created osimertinib-specific antibodies and developed an immunohistochemistry (IHC) for locating the sites of osimertinib action. Moreover, we located osimertinib–protein conjugates in intestinal, dermal, and lung tissues of rats, thereby using our IHC to visualize the sites of the adverse effects of osimertinib, including diarrhea, skin disorder, and interstitial pneumonia. This report is the first to elucidate the localization of the sites of action of osimertinib in the rat intestine, skin, and lung and is expected to help clarify the mechanism of osimertinib-induced adverse effects.</p>\n<p></p>","PeriodicalId":6888,"journal":{"name":"Acta Histochemica Et Cytochemica","volume":"29 1","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Histochemica Et Cytochemica","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1267/ahc.23-00055","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations and has shown efficacy in patients with non-small-cell lung cancer. In this study, we created osimertinib-specific antibodies and developed an immunohistochemistry (IHC) for locating the sites of osimertinib action. Moreover, we located osimertinib–protein conjugates in intestinal, dermal, and lung tissues of rats, thereby using our IHC to visualize the sites of the adverse effects of osimertinib, including diarrhea, skin disorder, and interstitial pneumonia. This report is the first to elucidate the localization of the sites of action of osimertinib in the rat intestine, skin, and lung and is expected to help clarify the mechanism of osimertinib-induced adverse effects.

用免疫组化方法确定奥希替尼在大鼠肠道、皮肤和肺部的作用部位
奥西默替尼是表皮生长因子受体(EGFR)的第三代不可逆酪氨酸激酶抑制剂(TKI),可选择性抑制EGFR-TKI致敏突变和EGFR T790M耐药突变,在非小细胞肺癌患者中显示出疗效。在这项研究中,我们创建了奥西美替尼特异性抗体,并开发了一种用于定位奥西美替尼作用位点的免疫组织化学(IHC)方法。此外,我们还在大鼠的肠道、皮肤和肺部组织中找到了奥希替尼-蛋白共轭物,从而利用我们的免疫组化技术观察到了奥希替尼不良反应的部位,包括腹泻、皮肤病和间质性肺炎。该报告首次阐明了奥希替尼在大鼠肠道、皮肤和肺部的作用位点定位,有望帮助阐明奥希替尼引发不良反应的机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Histochemica Et Cytochemica
Acta Histochemica Et Cytochemica 生物-细胞生物学
CiteScore
3.50
自引率
8.30%
发文量
17
审稿时长
>12 weeks
期刊介绍: Acta Histochemica et Cytochemica is the official online journal of the Japan Society of Histochemistry and Cytochemistry. It is intended primarily for rapid publication of concise, original articles in the fields of histochemistry and cytochemistry. Manuscripts oriented towards methodological subjects that contain significant technical advances in these fields are also welcome. Manuscripts in English are accepted from investigators in any country, whether or not they are members of the Japan Society of Histochemistry and Cytochemistry. Manuscripts should be original work that has not been previously published and is not being considered for publication elsewhere, with the exception of abstracts. Manuscripts with essentially the same content as a paper that has been published or accepted, or is under consideration for publication, will not be considered. All submitted papers will be peer-reviewed by at least two referees selected by an appropriate Associate Editor. Acceptance is based on scientific significance, originality, and clarity. When required, a revised manuscript should be submitted within 3 months, otherwise it will be considered to be a new submission. The Editor-in-Chief will make all final decisions regarding acceptance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信